Mary Thistle is Director of Alaunos Therapeutics, Inc.. Currently has a direct ownership of 45,000 shares of TCRT, which is worth approximately $93,600. The most recent transaction as insider was on Jun 22, 2022, when has been sold 40,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 45K
0% 3M change
0% 12M change
Total Value Held $93,600

Mary Thistle Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 22 2022
BUY
Grant, award, or other acquisition
-
40,000 Added 47.06%
45,000 Common Stock
Jun 22 2022
BUY
Grant, award, or other acquisition
-
40,000 Added 47.06%
45,000 Common Stock
Mar 04 2021
BUY
Grant, award, or other acquisition
-
5,000 Added 50.0%
5,000 Common Stock

Also insider at

FIXX
Homology Medicines, Inc. Healthcare
TRDA
Entrada Therapeutics, Inc. Healthcare
VIGL
Vigil Neuroscience, Inc. Healthcare
CGEM
Cullinan Oncology, Inc. Healthcare
MT

Mary Thistle

Director
Boston, MA

Track Institutional and Insider Activities on TCRT

Follow Alaunos Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TCRT shares.

Notify only if

Insider Trading

Get notified when an Alaunos Therapeutics, Inc. insider buys or sells TCRT shares.

Notify only if

News

Receive news related to Alaunos Therapeutics, Inc.

Track Activities on TCRT